Study Reveals New Insights into Rare Blood Cancer Development

Philadelphia chromosome–negative myeloproliferative neoplasms (MPNs) are rare blood cancers that cause excessive production of red cells, certain white blood cells, or platelets. Many cases are driven by a mutation in the JAK2 gene, called the JAK2V617F mutation, but how this mutation behaves in people before disease onset is unclear. Clarifying whether carriers inevitably progress to malignancy would refine surveillance strategies. New findings demonstrate that the JAK2V617F mutation does not always lead to blood cancer and characterize its clonal dynamics in a general-population cohort.

A research team from North Carolina State University (NC State; Raleigh, NC, USA) created a stochastic mathematical model to analyze how the JAK2V617F mutation expands within hematopoietic stem cells. The approach uses longitudinal variant allele fraction (VAF) measurements to quantify the proportion of mutated versus non-mutated JAK2 copies in peripheral blood. By modeling VAF trajectories, the study characterizes competitive behavior of mutant and wild‑type clones over time.

The researchers analyzed blood samples and health questionnaires from residents of Zealand, Denmark. Among nearly 20,000 participants, 67 individuals carrying JAK2V617F were identified. For these carriers, VAF data were available across a 10-year period, providing a population-based view of clonal evolution prior to clinical diagnosis. According to authors, most work on this mutation has focused on VAF in cancer patients, while understanding disease progression from a healthy state requires examining VAF before cancer develops.

Modeling indicated that in 70% of cases mutated cells were likely to outcompete normal counterparts, in 18% mutants showed a competitive disadvantage, and in 12% neither advantage nor disadvantage was observed. Of the 67 carriers, 37 were subsequently diagnosed with a myeloproliferative neoplasm, fewer than expected based on prior research. The results suggest that the presence of JAK2V617F alone does not uniformly predict malignant transformation.

The research was published in the Proceedings of the National Academy of Sciences on June 17, 2026. The work was conducted in Denmark, with the study completed at Roskilde University. According to the authors, the work offers insight into the earliest phases of disease development and may eventually inform tailored monitoring strategies for individuals with detectable JAK2V617F. The team noted that forthcoming analyses will evaluate additional influences on clonal behavior, including chronic inflammation. These directions aim to clarify why some carriers progress while others do not.

“We were fortunate to have access to a population study that allowed us to look at the occurrence of this mutation in the general public. That allowed us to see relationships between the mutation and instances of disease,” said Jordan Snyder, assistant teaching professor of mathematics at North Carolina State University and corresponding author of the study.

“While the exact mechanism of action from this mutation is not completely understood, the previous assumption was that the mutation would always eventually outcompete healthy copies, leading to cancer. But these data point to the idea that there is more to it. It's not just the presence of the mutated gene—something is happening to help that mutated copy outcompete the normal ones. Next steps in this work will be looking at some of those potential other factors—such as chronic inflammation,” said Snyder.

Related Links
NC State